Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO7566802 · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| Dose Escalation Cohort | EXPERIMENTAL | Participants in successive cohorts will receive escalating doses of RO7566802, as an intravenous (IV) infusion on Day 1 of each 21-day cycle followed by RO7566802 in combination with a fixed dose of atezolizumab, as an IV infusion on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity. |
| Dose Expansion Cohort | EXPERIMENTAL | Participants with select solid tumors will receive a recommended dose of RO7566802, determined in Dose Escalation phase, as an IV infusion in combination with a fixed dose of atezolizumab, as an IV infusion on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity. |
| Name | Type | Description |
|---|---|---|
| RO7566802 | DRUG | RO7566802 solution for infusion will be administered as specified in each treatment arm. |
| Atezolizumab | DRUG | Atezolizumab solution for infusion will be administered as specified in each treatment arm. |
Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1 * Life expectancy \>=3 months, in the investigator's judgment * Adequate hematologic and end-organ function * Histologically confirmed locally advanced, recurrent, or metastatic incurable solid tumor malignanc...
RO7566802 is an investigational small molecule being developed for the treatment of locally advanced solid tumors, as well as recurrent and metastatic solid tumors. It is currently being evaluated in a Phase 1 clinical trial in oncology.
RO7566802 is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company is conducting a Phase 1 clinical trial to evaluate the drug as a single agent and in combination with atezolizumab.
RO7566802 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing trial is active but not recruiting participants.
RO7566802 is being studied in a Phase 1 trial with the identifier NCT06031441. This trial evaluates the safety, pharmacokinetics, and activity of RO7566802 as a single agent and in combination with atezolizumab in participants with locally advanced or metastatic solid tumors.
Yes, RO7566802 is being studied both as a single agent and in combination with atezolizumab in a Phase 1 clinical trial. The trial is designed to evaluate the safety, pharmacokinetics, and activity of these treatment regimens in patients with solid tumors.
The RO7566802 clinical trial, NCT06031441, is being conducted in multiple countries, including the United States, Australia, Canada, Singapore, and the United Kingdom. The trial enrolls adults aged 18 years and older with locally advanced, recurrent, or metastatic solid tumors.